Anemia
Conference Coverage
Hydroxyurea well tolerated in longitudinal European study
WASHINGTON – Fewer than one in five adults experienced treatment-related adverse events and no secondary malignancies have been observed,...
News
FDA lifts hold on trial of MYC inhibitor
The US Food and Drug Administration (FDA) has lifted the clinical hold on a phase 1b trial of APTO-253. APTO-253 is a small molecule that...
Conference Coverage
Voxelotor cut transfusions in compassionate use sickle cell cohort
WASHINGTON – Hospitalizations and transfusions were down by about two-thirds in this severely affected group.
Conference Coverage
Voxelotor benefits adolescents with SCD
STOCKHOLM—An ongoing phase 2 study suggests voxelotor (GBT440) can benefit adolescents with sickle cell disease (SCD). In the HOPE-KIDS 1 study,...
News
Leading researcher in genetics, hematology dies at 84
George Stamatoyannopoulos, MD, who conducted important research into hemoglobinopathies, passed away this month at the age of 84. Dr...
Conference Coverage
Drug is convenient alternative for PNH, doc says
STOCKHOLM—Results of a phase 3 study suggest the long-acting C5 complement inhibitor ravulizumab produces similar results as eculizumab in...
Conference Coverage
Sickle cell disease exacts a heavy vocational toll
WASHINGTON – “This is a dream deferred” for patients and families affected by sickle cell disease.
Conference Coverage
Family engagement can buffer early cognitive hit from SCD
WASHINGTON –
News
Mircera approved for anemia in pediatric patients with CKD
Mircera®, methoxy polyethylene glycol-epoetin beta, was approved by the US Food and Drug Administration (FDA) to treat anemia in pediatric...
News from the FDA/CDC
FDA approves long-acting ESA for dialysis-related anemia in children, adolescents
Mircera is now indicated for dialysis-related anemia in patients aged 5-17 years with chronic kidney disease.
News
FDA approves first biosimilar pegfilgrastim
The US Food and Drug Association (FDA) has approved pegfilgrastim-jmdb (Fulphila™) as the first biosimilar to Neulasta®. The agents reduce the...